Seres Therapeutics (MCRB) Insider Trading & Ownership $0.55 -0.04 (-6.78%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Seres Therapeutics (NASDAQ:MCRB) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$66,404.39 Get MCRB Insider Trade Alerts Want to know when executives and insiders are buying or selling Seres Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MCRB Insider Buying and Selling by Quarter Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Seres Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails10/28/2024Eric D ShaffCEOSell8,748$0.69$6,036.12 10/28/2024Moltke Lisa VonInsiderSell4,334$0.69$2,990.46 10/28/2024Thomas DesrosierEVPSell4,259$0.69$2,938.71 8/16/2024Eric D ShaffCEOSell2,518$0.84$2,115.12 8/16/2024Moltke Lisa VonInsiderSell973$0.84$817.32 8/16/2024Thomas DesrosierEVPSell873$0.84$733.32 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/5/2024Teresa L YoungInsiderSell24,480$1.08$26,438.40 5/15/2024Eric D ShaffCEOSell2,435$0.94$2,288.90 5/15/2024Moltke Lisa VonInsiderSell939$0.94$882.66 5/15/2024Thomas DesrosierEVPSell843$0.94$792.42 2/16/2024David ArkowitzCFOSell3,939$1.08$4,254.12 2/16/2024Eric D ShaffCEOSell11,549$1.08$12,472.92 2/16/2024Teresa L YoungInsiderSell3,374$1.08$3,643.92 (Data available from 1/1/2013 forward) MCRB Insider Trading Activity - Frequently Asked Questions Who is on Seres Therapeutics's Insider Roster? The list of insiders at Seres Therapeutics includes David Arkowitz, David S Ege, Eric D Shaff, Health Ltp Fund Ge Nutritional, Moltke Lisa Von, Paula Cloghessy, Teresa L Young, and Thomas Desrosier. Learn more on insiders at MCRB. What percentage of Seres Therapeutics stock is owned by insiders? 5.10% of Seres Therapeutics stock is owned by insiders. Learn more on MCRB's insider holdings. Which Seres Therapeutics insiders have been selling company stock? The following insiders have sold MCRB shares in the last 24 months: David Arkowitz ($9,743.22), David S Ege ($36,527.22), Eric D Shaff ($34,458.26), Moltke Lisa Von ($4,690.44), Paula Cloghessy ($3,920.40), Teresa L Young ($30,082.32), and Thomas Desrosier ($10,075.05). How much insider selling is happening at Seres Therapeutics? Insiders have sold a total of 95,980 Seres Therapeutics shares in the last 24 months for a total of $129,496.91 sold. Seres Therapeutics Key ExecutivesMr. Eric D. Shaff M.B.A. (Age 48)President, CEO & Director Compensation: $1.02M2 recent tradesDr. Lisa von Moltke M.D. (Age 65)Executive VP & Chief Medical Officer Compensation: $725.15kDr. Teresa L. Young Ph.D. (Age 57)R.Ph., Executive VP and Chief Commercial & Strategy Officer Compensation: $606.33kMs. Marella Thorell (Age 57)Executive VP & CFO Dr. David S. Ege Ph.D. (Age 49)Executive VP & Chief Technology Officer Compensation: $142.71kDr. Matthew R. Henn Ph.D. (Age 49)Executive VP & Chief Scientific Officer Compensation: $643.83kMr. Carlo Tanzi Ph.D.Investor Relations OfficerMr. Thomas J. DesRosier Esq. (Age 69)J.D., Chief Legal Officer, Executive VP & Secretary Compensation: $719.55kMs. Caroline HoldaAssistant General Counsel More Insider Trading Tools from MarketBeat Related Companies FibroGen Insider Ownership Nektar Therapeutics Insider Ownership Terns Pharmaceuticals Insider Ownership Aquestive Therapeutics Insider Ownership ChromaDex Insider Ownership KalVista Pharmaceuticals Insider Ownership Ginkgo Bioworks Insider Ownership Zevra Therapeutics Insider Ownership Amylyx Pharmaceuticals Insider Ownership Esperion Therapeutics Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:MCRB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts